OUR STORY SO FAR
CanniOasis: From cells to cures: Pioneering human brain organoid models to accelerate neurological breakthroughs to improve the lives of patients worldwide — rooted in innovation, driven by purpose
Incorporated Aug 2021, Dr Lim Kah Meng set out a vision to provide a quicker, safer, humane and cost-effective solution for pharmaceutical companies to perform neuro-clinical testing.
We develop human midbrain organoid from induced pluripotent stem cells (iPSCs) via working with A*Star and National University of Singapore, allowing the development precision drugs and supplements.
We have patented the technique to extract atypical cannabinoids essence from plants incl. black pepper, truffles.
There is no known competitor in the world in the space of developing midbrain organoid model for screening, validation technologies and drug development strategies.
